PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer's disease

Experimental Gerontology

Volumn 48, Issue 7, 2013, Pages 647-653

  O'Neill, Cora ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Alzheimer's disease; Insulin; Insulin like growth factor; Longevity; PI3 kinase Akt mTOR

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; LIRAGLUTIDE; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR ANTAGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN C; TAU PROTEIN; TRANSCRIPTION FACTOR FOXO;

AGING; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CALORIC RESTRICTION; CELL POLARITY; COGNITIVE DEFECT; DRUG PENETRATION; FRAGILE X SYNDROME; HUMAN; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MILD COGNITIVE IMPAIRMENT; NERVE CELL LESION; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN TARGETING; REVIEW; RISK FACTOR;

AGE FACTORS; AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION; COGNITION DISORDERS; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

ANIMALIA; MAMMALIA;

EID: 84879026548     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.02.025     Document Type: Review

References (63)

1. Arendt T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol. 2003, 71:83-248.
2. Bhaskar K., Miller M., Chludzinski A., Herrup K., Zagorski M., Lamb B.T. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol. Neurodegener. 2009, 4:14.
3. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Invest. 2012, 122:1339-1353.
4. Bonafe M., Barbieri M., Marchegiani F., Olivieri F., Ragno E., Giampieri C., Mugianesi E., Centurelli M., Franceschi C., Paolisso G. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J. Clin. Endocrinol. Metab. 2003, 88:3299-3304.
5. Bradley C.A., Peineau S., Taghibiglou C., Nicolas C.S., Whitcomb D.J., Bortolotto Z.A., Kaang B.K., Cho K., Wang Y.T., Collingridge G.L. A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 2012, 5:13.
6. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285:13107-13120.
7. Caccamo A., Maldonado M.A., Majumder S., Medina D.X., Holbein W., Magri A., Oddo S. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J. Biol. Chem. 2011, 286:8924-8932.
8. Chiang H.C., Wang L., Xie Z., Yau A., Zhong Y. PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7060-7065.
9. Cohen E., Paulsson J.F., Blinder P., Burstyn-Cohen T., Du D., Estepa G., Adame A., Pham H.M., Holzenberger M., Kelly J.W., Masliah E., Dillin A. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139:1157-1169.
10. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 2005, 26(Suppl. 1):65-69.
11. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
12. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
13. de la Monte S.M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:35-66.
14. Douglas P.M., Dillin A. Protein homeostasis and aging in neurodegeneration. J. Cell Biol. 2010, 190:719-729.
15. Ehninger D., de Vries P.J., Silva A.J. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J. Intellect. Disabil. Res. 2009, 53:838-851.
16. Flachsbart F., Caliebe A., Kleindorp R., Blanche H., von Eller-Eberstein H., Nikolaus S., Schreiber S., Nebel A. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2700-2705.
17. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
18. Garelick M.G., Kennedy B.K. TOR on the brain. Exp. Gerontol. 2011, 46:155-163.
19. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 2005, 93:105-117.
20. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
21. Hers I., Vincent E.E., Tavare J.M. Akt signalling in health and disease. Cell. Signal. 2011, 23:1515-1527.
22. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 2011, 3:77sr71.
23. Holzenberger M., Dupont J., Ducos B., Leneuve P., Geloen A., Even P.C., Cervera P., Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003, 421:182-187.
24. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J. Neural Transm. 1998, 105:415-422.
25. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
26. Ittner L.M., Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
27. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
28. Jiang H., Guo W., Liang X., Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 2005, 120:123-135.
29. Johnson T.E. Caenorhabditis elegans 2007: the premier model for the study of aging. Exp. Gerontol. 2008, 43:1-4.
30. Kenyon C.J. The genetics of ageing. Nature 2010, 464:504-512.
31. Kenyon C. The first long-lived mutants: discovery of the insulin/IGF-1 pathway for ageing. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 366:9-16.
32. Kloet D.E., Burgering B.M. The PKB/FOXO switch in aging and cancer. Biochim. Biophys. Acta 2011, 1813:1926-1937.
33. Kwak Y.D., Ma T., Diao S., Zhang X., Chen Y., Hsu J., Lipton S.A., Masliah E., Xu H., Liao F.F. NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol. Neurodegener. 2010, 5:49.
34. Li X., Alafuzoff I., Soininen H., Winblad B., Pei J.J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005, 272:4211-4220.
35. Long-Smith C.M., Manning S., McClean P.L., Coakley M.F., O'Halloran D.J., Holscher C., O'Neill C. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med. 2013, 15(1):102-114. 10.1007/s12017-012-8199-5.
36. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., Chen P.P., Hudspeth B., Chen C., Zhao Y., Vinters H.V., Frautschy S.A., Cole G.M. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009, 29:9078-9089.
37. Majumder S., Caccamo A., Medina D.X., Benavides A.D., Javors M.A., Kraig E., Strong R., Richardson A., Oddo S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 2012, 11:326-335.
38. Martin E.D., Sanchez-Perez A., Trejo J.L., Martin-Aldana J.A., Cano Jaimez M., Pons S., Acosta Umanzor C., Menes L., White M.F., Burks D.J. IRS-2 deficiency impairs NMDA receptor-dependent long-term potentiation. Cereb. Cortex 2012, 22:1717-1727.
39. McClean P.L., Parthsarathy V., Faivre E., Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
40. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
41. Morita T., Sobue K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J. Biol. Chem. 2009, 284:27734-27745.
42. Morris M., Maeda S., Vossel K., Mucke L. The many faces of tau. Neuron 2011, 70:410-426.
43. O'Neill C., Kiely A.P., Coakley M.F., Manning S., Long-Smith C.M. Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. Biochem. Soc. Trans. 2012, 40:721-727.
44. Pei J.J., Hugon J. mTOR-dependent signalling in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:2525-2532.
45. Pei J.J., Khatoon S., An W.L., Nordlinder M., Tanaka T., Braak H., Tsujio I., Takeda M., Alafuzoff I., Winblad B., Cowburn R.F., Grundke-Iqbal I., Iqbal K. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol. (Berl.) 2003, 105:381-392.
46. Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., Lo E., Wu D., Saule E., Bouschet T., Matthews P., Isaac J.T., Bortolotto Z.A., Wang Y.T., Collingridge G.L. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007, 53:703-717.
47. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
48. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.Q., Palop J.J., Noebels J.L., Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:700-711.
49. Selkoe D., Mandelkow E., Holtzman D. Deciphering Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a011460.
50. Selman C., Tullet J.M., Wieser D., Irvine E., Lingard S.J., Choudhury A.I., Claret M., Al-Qassab H., Carmignac D., Ramadani F., Woods A., Robinson I.C., Schuster E., Batterham R.L., Kozma S.C., Thomas G., Carling D., Okkenhaug K., Thornton J.M., Partridge L., Gems D., Withers D.J. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
51. Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004, 14:1650-1656.
52. Sonoda Y., Mukai H., Matsuo K., Takahashi M., Ono Y., Maeda K., Akiyama H., Kawamata T. Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. Neurosci. Lett. 2010, 471:20-24.
53. Suh Y., Atzmon G., Cho M.O., Hwang D., Liu B., Leahy D.J., Barzilai N., Cohen P. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3438-3442.
54. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
55. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9:753-762.
56. Townsend M., Mehta T., Selkoe D.J. Soluble abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282:33305-33312.
57. van Heemst D., Beekman M., Mooijaart S.P., Heijmans B.T., Brandt B.W., Zwaan B.J., Slagboom P.E., Westendorp R.G. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell 2005, 4:79-85.
58. 5-dependent translation of amyloid precursor protein. PLoS Biol. 2007, 5:e52.
59. Wu Y.T., Ouyang W., Lazorchak A.S., Liu D., Shen H.M., Su B. mTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif. J. Biol. Chem. 2011, 286:14190-14198.
60. Yoshimura T., Arimura N., Kaibuchi K. Signaling networks in neuronal polarization. J. Neurosci. 2006, 26:10626-10630.
61. Zhang X., Li F., Bulloj A., Zhang Y.W., Tong G., Zhang Z., Liao F.F., Xu H. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J. 2006, 20:1272-1274.
62. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260.
63. Zhao W.Q., Lacor P.N., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J. Biol. Chem. 2009, 284:18742-18753.